Literature DB >> 11557486

Effects of AIDS and gender on steady-state plasma and intrapulmonary ethambutol concentrations.

J E Conte1, J A Golden, J Kipps, E T Lin, E Zurlinden.   

Abstract

Our objective was to study the steady-state plasma and intrapulmonary orally administered ethambutol concentrations in healthy volunteers and subjects with AIDS. Ethambutol (15 mg/kg of body weight) was administered orally once daily to 10 men with AIDS, 10 healthy men, 10 women with AIDS, and 10 healthy women. The mean (+/-standard deviation [SD]) CD4 cell count for the 20 subjects with AIDS was (350 +/- 169) x 10(6) cells per liter. Blood was obtained for drug assay 2 h after the last dose and at the completion of bronchoalveolar lavage, performed 4 h after the last dose. Standardized bronchoscopy was performed without systemic sedation. The volume of epithelial lining fluid (ELF) was calculated by the urea dilution method. The total number of alveolar cells (AC) was counted in a hemocytometer, and differential cell counting was performed after cytocentrifugation. Ethambutol was measured by a new, sensitive and specific liquid chromotography-mass spectrometry method. The presence of AIDS, as defined in this study, or gender was without significant effect on the concentrations of ethambutol in plasma at 2 or 4 h or in ELF at 4 h following the last dose. Plasma drug concentrations (mean +/- SD) at 2 and 4 h were 2.1 +/- 1.2 and 2.1 +/- 0.8 microg/ml, respectively, and both values were not significantly different from the concentration of ethambutol in ELF at 4 h (2.2 +/- 1.1 microg/ml). The concentration of ethambutol was significantly greater in AC in all four groups (range, 44.5 +/- 15.6 to 82.0 +/- 39.4 microg/ml) than in ELF or plasma and was approximately 30 to 240 times the reported MIC for ethambutol-susceptible strains of Mycobacterium tuberculosis. The AC ethambutol concentration (mean +/- SD) in the smoking women (97.2 +/- 32.1 microg/ml) was more than twice the concentration in all other nonsmoking subjects (45.2 +/- 16.8 microg/ml) combined (P < 0.05). Two- and 4-h concentrations of ethambutol in plasma were not affected by AIDS status or gender. The high AC/plasma and AC/ELF concentration ratios suggest that substantial antimycobacterial activity resides in these cells. The data confirm earlier observations of active transport ex vivo of ethambutol into pulmonary macrophages.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557486      PMCID: PMC90748          DOI: 10.1128/AAC.45.10.2891-2896.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

Review 1.  Pulmonary disposition of antimicrobial agents: methodological considerations.

Authors:  D R Baldwin; D Honeybourne; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

2.  [ENZYMATIC UREA DETERMINATION IN THE BLOOD AND SERUM IN THE WARBURG OPTICAL TEST].

Authors:  H TALKE; G E SCHUBERT
Journal:  Klin Wochenschr       Date:  1965-02-01

Review 3.  Immunopathology of tuberculosis: roles of macrophages and monocytes.

Authors:  M J Fenton; M W Vermeulen
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

4.  Low antituberculosis drug concentrations in patients with AIDS.

Authors:  C A Peloquin; A T Nitta; W J Burman; K F Brudney; J R Miranda-Massari; M E McGuinness; S E Berning; G T Gerena
Journal:  Ann Pharmacother       Date:  1996-09       Impact factor: 3.154

5.  In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages.

Authors:  N Rastogi; V Labrousse; K S Goh
Journal:  Curr Microbiol       Date:  1996-09       Impact factor: 2.188

6.  Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea.

Authors:  S H Choudhri; M Hawken; S Gathua; G O Minyiri; W Watkins; J Sahai; D S Sitar; F Y Aoki; R Long
Journal:  Clin Infect Dis       Date:  1997-07       Impact factor: 9.079

7.  Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects.

Authors:  J E Conte; J Golden; S Duncan; E McKenna; E Lin; E Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

8.  From the Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.

Authors: 
Journal:  JAMA       Date:  1993-02-10       Impact factor: 56.272

9.  Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin.

Authors:  J E Conte; J A Golden; S Duncan; E McKenna; E Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

10.  Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease.

Authors:  S M Gordon; C R Horsburgh; C A Peloquin; J A Havlik; B Metchock; L Heifets; J E McGowan; S E Thompson
Journal:  J Infect Dis       Date:  1993-12       Impact factor: 5.226

View more
  21 in total

Review 1.  Interpretation of antibiotic concentration ratios measured in epithelial lining fluid.

Authors:  Sungmin Kiem; Jerome J Schentag
Journal:  Antimicrob Agents Chemother       Date:  2007-09-10       Impact factor: 5.191

Review 2.  Inhaled drug delivery for tuberculosis therapy.

Authors:  Pavan Muttil; Chenchen Wang; Anthony J Hickey
Journal:  Pharm Res       Date:  2009-11       Impact factor: 4.200

Review 3.  Pharmacologic considerations in use and development of antituberculosis drugs.

Authors:  Geraint Davies
Journal:  Cold Spring Harb Perspect Med       Date:  2014-09-18       Impact factor: 6.915

4.  Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol.

Authors:  Shashikant Srivastava; Sandirai Musuka; Carleton Sherman; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  J Infect Dis       Date:  2010-04-15       Impact factor: 5.226

5.  Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium.

Authors:  Devyani Deshpande; Shashikant Srivastava; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

Review 6.  Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.

Authors:  Roger K Verbeeck; Gunar Günther; Dan Kibuule; Christian Hunter; Tim W Rennie
Journal:  Eur J Clin Pharmacol       Date:  2016-06-15       Impact factor: 2.953

7.  New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.

Authors:  Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

8.  Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Marina McIver; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Steady-state plasma and intrapulmonary pharmacokinetics and pharmacodynamics of cethromycin.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.

Authors:  Keith A Rodvold; Larry H Danziger; Mark H Gotfried
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.